

03/30/00
jc781 U.S. PTO

03-31-00

Date of Deposit March 30, 2000

A

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 358594-00010-2

First Inventor or Application Identifier Pankaj Modi

Title Method for Administering Insulin to the

Express Mail Label No. EJ924755102US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 52]
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]
4. Oath or Declaration [Total Pages 2]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. § 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
11. ☒ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☒ * Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired
(PTO/SB/09-12)
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☐ Other:

* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 09,216,733**

Prior application information: Examiner Todd D. Ware Group / Art Unit: 1615

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name	Diane R. Meyers				
	Eckert Seamans Cherin & Mellott, LLC				
Address	600 Grant Street, 44th Floor				
City	Pittsburgh	State	PA	Zip Code	15219
Country	US	Telephone	412/566-2036	Fax	412/566-6099

Name (Print/Type)	Diane R. Meyers	Registration No. (Attorney/Agent)	38,968
Signature		Date	March 30, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

*Buccal Region

**which is a CIP of 09/021,114

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(c))--SMALL BUSINESS CONCERN

Docket Number (Optional)
358594-00010-2

Applicant, Patentee, or Identifier: Pankaj Modi
Application or Patent No.: _____
Filed or Issued: _____
Title: Method for Administering Insulin to the Buccal Region

I hereby state that I am

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Generex Biotechnology Corporation

ADDRESS OF SMALL BUSINESS CONCERN 33 Harbour Square, Suite 202
Toronto, Ontario Canada M5J 2G2

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.
☐ each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Anna Gluskin

TITLE OF PERSON IF OTHER THAN OWNER President

ADDRESS OF PERSON SIGNING 33 Harbour Square, Suite 202, Toronto, Ontario
Canada M5J 2G2

SIGNATURE  DATE March 30, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application Of : Group Art Unit:
:
PANKAJ MODI : Examiner:
:
(Continuation-in-Part :
of Application Serial No. : Attorney Docket No. 358594-00010-2
09/216,733, filed :
December 21, 1998, which is :
a CIP of 09/021,114, filed :
February 10, 1998 (now U.S. Patent :
No. 6,017,545, issued on :
January 25, 2000) :
:
Entitled :
:
METHOD FOR ADMINISTERING :
INSULIN TO THE BUCCAL REGION :

PRELIMINARY AMENDMENT

March 27, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231
Attn: BOX PATENT APPLICATION

Sir:

Please enter the following amendment and consider the following remarks prior to examination. This application is a continuation-in-part application of Application Serial No. 09/216,733 which in turn was a CIP of Application Serial No. 09/021,114 (now U.S. Patent No. 6,017,545, issued on January 25, 2000).

Please amend the above-identified application as follows:

In the Abstract:

Please add the following sentence as the last sentence of the abstract:

-- Methods for administering insulin to the buccal region are also disclosed --.

[illegible]

On page 7, line 27, after “propellant” insert -- , --.

On page 10, line 24, delete “i”).

On page 10, line 27, delete “i”).

On page 11, line 20, after “is” insert -- in a ratio practiced in the art,

On page 11, line 28, after “dispenser” insert -- known in the arts for aerosol administration of drugs --.

On page 16, line 29, after “propellant” insert -- known for use with dispensers --.

On page 19, line 6, after "propellant" insert -- in a manner known in the art --.

On page 19, line 7, after “propellants” insert -- in the art --.

On page 22, line 4, after “propellant” insert - in a manner known in the art --.

Please cancel Claims 1-25.

Please add the following new claims:

~~26.~~ A method for administering insulin to the buccal mucosa using a metered dose inhaler.

27. The method of Claim 26, wherein said insulin is in a mixed micelle formulation.

hyaluronate and bacitracin; and vi) sodium lauryl sulfate, sodium salicylate, disodium edetate, sodium hyaluronate, oleic acid and gamma linoleic acid.

35. The method of Claim 27, wherein said insulin is administered in an effective amount. --

REMARKS

The present case contains newly added claims directed to methods for administering insulin to the buccal region, specifically the buccal mucosa, using a metered dose inhaler. Support for the added claims is found throughout the specification as filed, for example, on page 22, lines 25-30. It is submitted, therefore, that no new matter is added.

Respectfully submitted,



Diane R. Meyers
Registration No. 38,968
Eckert Seamans Cherin & Mellott, LLC
600 Grant Street, 44th Floor
Pittsburgh, PA 15219
Attorney for Applicant

(412) 566-2036

[illegible]

7

10

20

25

30

Scientists have explored various administration routes other than the injection for proteins and peptides. These routes include oral, intranasal, rectal,

000000 " 62888880

vaginal cavities for the effective delivery of large molecules. Out of the above four mentioned routes oral and nasal cavities have been of greatest interest to scientists. Both the oral and nasal membranes offer 5 advantages over other routes of administration. For example, drugs administered through these membranes have a rapid onset of action, provide therapeutic plasma levels, avoid first pass effect of hepatic metabolism, and avoid exposure of the drug to hostile GI 10 environment. Additional advantages include easy access to the membrane sites so that the drug can be applied, localized and removed easily. Further, there is a good potential for prolonged delivery of large molecules through these membranes.

15 The oral routes have received far more attention than has the other routes. The sublingual mucosa includes the membrane of ventral surface of the tongue and the floor of the mouth whereas the buccal mucosa constitutes the lining of the cheek. The sublingual 20 mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many drugs. Further, the sublingual mucosa is convenient, acceptable and easily accessible. This route has been investigated clinically for the delivery of a substantial number of 25 drugs.

The ability of molecules to permeate through the oral mucosa appears to be related to molecular size, lipid solubility and peptide protein ionization. Small molecules, less than 1000 daltons appear to cross mucosa 30 rapidly. As molecular size increases, the permeability decreases rapidly. Lipid soluble compounds are more

Most proteinic drug molecules are extremely large molecules with molecular weight exceeding 6000 daltons. These large molecules have very poor lipid solubility and are practically impermeable. Substances that

Various mechanisms of action of enhancers have been
20 proposed. These mechanisms of action, at least for
protein and peptidic drugs include (1) reducing
viscosity and/or elasticity of mucous layer, (2)
facilitating transcellular transport by increasing the
fluidity of the lipid bilayer of membranes, and (3)
25 increasing the thermodynamic activity of drugs (Critical
Rev, 117-125, 1991, 1992).

Many enhancers have been tested so far and some have found to be effective in facilitating mucosal administration of large molecule drugs. However, hardly
30 any penetration enhancing products have reached the market place. Reasons for this include lack of a

000000" 62888860

satisfactory safety profile respecting irritation, lowering of the barrier function, and impairment of the mucocilliary clearance protective mechanism. The main factor to be considered in the use of enhancers

5 especially related to bile salts, and some protein solubilizing agents is extremely bitter and unpleasant taste. This makes their use almost impossible for human consumption on a daily basis. Several approaches were utilized to improve the taste of the bile salts based

10 delivery systems, but none one of them are commercially acceptable for human consumption to date. Among the approaches utilized includes patch for buccal mucosa, bilayer tablets, controlled release tablets, use of protease inhibitors, buccally administered film patch

15 devices, and various polymer matrices.

The basic problem associated with the above technologies is the use of large quantities of bile acids and their salts to promote the transport of the large molecules through membranes in the form of

20 localized delivery system using patches or tablets. In spite of using protease inhibitors and polymer coatings the technologies failed to deliver proteinic drugs in the required therapeutic concentrations. Further, the problem is compounded because of the localized site

25 effect of the patch which resulted in severe tissue damage in the mouth. Most attempts were made to deliver large molecules via the oral, nasal, rectal, and vaginal routes using single bile acids or enhancing agents in combination with protease inhibitors and biodegradable

30 polymeric materials. However, it is extremely difficult to achieve therapeutic levels of proteinic drugs using

these formulations. As single enhancing agents fails to loosen tight cellular junctions in the oral, nasal, rectal and vaginal cavities for a required period of time to allow passage of large molecules through the mucosal membranes without further degradation. This problem makes it impractical to use the above mentioned systems for a commercial purpose.

In order to overcome the above mentioned problem of the bitter taste, irritation and the penetration of large molecules through the sublingual, buccal and GI tract mucosal lining, a system has now been designed where protein drug was encapsulated in mixed micelles made up of combination of enhancers, e.g. yolk proteins (lecithins). This system allows opening of the paracellular junctions (tight junctions) in oral as well as in GI tract by GI motility movement with high degree of protease activity preserved and protecting molecules from premature degradation in the hostile acidic and proteolytic GI environment.

It is believed that the mixed micelles encapsulate molecules with high degree of efficiency (>90% encapsulation). These mixed micelles are extremely small in the size (1 nm to 10 nm), and are smaller than the pores of the membranes in the oral cavity or the GI tract. It is therefore believed that the extremely small size of mixed micelles helps encapsulated molecules penetrate efficiently through the mucosal membranes of the oral cavity.

The absorption of proteins and peptides is believed to be enhanced by the diffusion of large molecules entrapped in the mixed micellar form through the aqueous

pores and the cell structure perturbation of the tight paracellular junctions.

The amount of physiologically peptide or protein in the compositions of this invention is typically a quantity that provides an effective amount of the drug to produce the physiological activity (therapeutic plasma level) for which peptide or protein is being administered. In consideration of the fact that the bioavailability of any active substance can never be 100%, that is to say the administered dose of the active drug is not completely absorbed, it is preferable to incorporate slightly larger amount than the desired dosage. Where the dosage form is a spray (aerosol) or the like which is repeatedly dispensed from the same 15 container, it is recommendably so arranged that the unit dose will be slightly greater than the desired dose. It should be understood that dosage should vary with species of warm blood animals such as man, domestic animals, and their body weights. Although the 20 composition of this invention is prepared as the microfine droplets (1 to 10 nm or less) by the virtue of its preparation methods used and suitable combinations of enhancer compound characteristics. The utilization of atomizer or aerosol spray devices (metered dose 25 inhalers or nebulizers) may be useful to further a sufficient reduction of particle size for effective inhalation from the nasal or oral cavity so the drug may successfully absorbed or reach to the specific site.

The therapeutic composition of the present
30 invention can be stored at room temperature or at cold
temperature. Storage of proteinic drugs is preferable at

the cold temperature to prevent the degradation of the drugs and to extend their shelf life. While the mixed micellar therapeutic composition of the invention is applied to the mucosal membranes, the sites of
5 administration may be the same as those used for the usual mucosal therapeutic preparation. Generally, oral, transdermal and nasal are the favourite sites of the administration but the composition can be applied to the rectal and vaginal mucosa. According to the
10 physiologically active peptide or protein used, the dosage form and the site of administration, a specific administration method can be selected.

As used herein, the term "edetate" is used herein to refer to pharmaceutically acceptable salts of
15 ethylenediaminetetraacetic acid.

It has also been found that improvements in penetration and absorption of mixed micellar formulations can be achieved by mixing the mixed micellar formulation with propellants such as
20 tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants. Preferably they are delivered through metered dose spray devices. Metered dose inhalers are
25 known and are a popular pulmonary drug delivery form for some drugs. The present formulation, including the propellant is intended to improve the quality of absorption, stability and performance of many formulations. The compositions have been selected to
30 give enhancement in the penetration through pores, and facilitate absorption of the drugs to reach therapeutic

levels in the plasma. The present formulation may be absorbed buccally, by ensuring that the person does not inhale the formulation as it is sprayed. One of the other benefits of using an atomizer or inhaler is that
5 the potential for contamination is minimized because the devices are self contained.

Summary of the Invention

Accordingly the present invention provides a mixed micellar pharmaceutical formulation, having a pH of
10 between 6.0 and 7.0 comprising a proteinic pharmaceutical agent in micellar form, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt.% of the total formulation, a pharmaceutically acceptable edetate in a concentration of from 1 to 10
15 wt./wt.% of the total formulation, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the total formulation, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid,
20 pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin,
25 lysine, polylysine, triolein and mixtures thereof, wherein the amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt.%
30 of the formulation.

In an embodiment, the alkali metal lauryl sulphate,

000000" 5288560

the edetate and the alkali metal salicylate are each in a concentration of from 2 to 5 wt./wt.% of the total formulation.

In one embodiment, the edetate is an alkali metal edetate. Preferably the alkali metal edetate is be selected from the group consisting of disodium edetate, dipotassium edetate, and combinations thereof.

In another embodiment, the alkali metal lauryl sulphate is sodium lauryl sulphate.

10 In a further embodiment, the alkali metal
salicylate is sodium salicylate.

In another embodiment, the lecithin is selected from the group consisting of saturated phospholipid, e.g. Phospholipon-H (trade mark) saturated phospholipid, 15 unsaturated phospholipid, e.g. Phospholipon-G (trade mark) unsaturated phospholipid, phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.

In one embodiment, one of the absorption enhancing
20 compounds is selected from the group consisting of
hyaluronic acid, pharmaceutically acceptable salts of
hyaluronic acid and mixtures thereof, the concentration
such micelle forming compound being from about 1 to
about 5 wt./wt. %.

25 In another embodiment, suitable for delivery through nasal passages, mixed micellar pharmaceutical formulation is suitably diluted to avoid irritation of the nasal passages.

Another aspect of the present invention provides a
30 mixed micellar pharmaceutical formulation, comprising a
pharmaceutical agent in micellar form, water, an alkali

Yet another aspect of the present invention provides that the mixed micellar aerosol pharmaceutical formulation additionally comprises i) a phenol selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and ii) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.

Yet another aspect of the present invention provides that the mixed micellar aerosol pharmaceutical formulation additionally comprises i) a phenol selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and ii) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.

In one embodiment, the alkali metal C8 to C22 alkyl sulphate is in a concentration of from 2 to 5 wt./wt.% of the total formulation.

In another embodiment, the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.

In another embodiment, the lecithin is saturated or unsaturated, preferably selected from the group consisting of phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.

In yet another embodiment, one of the micelle forming compounds is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, polidocanol alkyl ethers, trihydroxy oxo cholanyl glycine, polyoxyethylene ethers and mixtures thereof, the concentration such absorption enhancing compound being from about 1 to about 5 wt./wt.%.

Preferably, the ratio of pharmaceutical agent, e.g. insulin, to propellant is from 5:95 to 25:75.

In another embodiment, the propellant is selected from the group consisting of tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.

In yet another embodiment, the mixed micellar pharmaceutical formulation is contained in an aerosol dispenser.

For insulin-containing and some other compositions, the composition may also contains at least one inorganic salt which opens channels in the gastrointestinal tract

and may provide additional stimulation to release insulin. Non-limiting examples of inorganic salts are sodium, potassium, calcium and zinc salts, especially sodium chloride, potassium chloride, calcium chloride, zinc chloride and sodium bicarbonate.

It will be recognized by those skilled in the art that for many pharmaceutical compositions it is usual to add at least one antioxidant to prevent degradation and oxidation of the pharmaceutically active ingredients.

10 It will also be understood by those skilled in the art that colorants, flavouring agents and non-therapeutic amounts of other compounds may be included in the formulation. Typical flavouring agents are menthol and sorbitol.

15 In one embodiment the antioxidant is selected from the group consisting of tocopherol, deteroxime mesylate, methyl paraben, ethyl paraben and ascorbic acid and mixtures thereof. A preferred antioxidant is tocopherol.

20 In a preferred embodiment at least one protease inhibitor is added to the formulation to inhibit degradation of the pharmaceutical agent by the action of proteolytic enzymes. Of the known protease inhibitors, most are effective at concentrations of from 1 to 25 3 wt./wt.% of the formulation.

Non-limiting examples of effective protease inhibitors are bacitracin, soyabean trypsin, aprotinin and bacitracin derivatives, e.g. bacitracin methylene disalicylate. Bacitracin is the most effective of those named when used in concentrations of from 1.5 to 2 wt./wt.%. Soyabean trypsin and aprotinin two may be

The formulation suitable for delivery through oral mucosal membranes may be in chewable form, in which case it will be necessary to add ingredients suitable for such form. Such ingredients include guar gum, powdered acacia, carrageenin, beeswax and xanthan gum.

25 The present invention also provides a process for making a pharmaceutical composition suitable for delivery through transdermal membranes comprising:

a) preparing a proteinic pharmaceutical agent composition in micellar form in an aqueous medium which

30 has an alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar

pharmaceutical agent composition, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition and a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition;

b) slowly adding the micellar proteinic pharmaceutical agent composition to at least one of the absorption enhancing compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof, while mixing vigorously, to form a mixed micellar composition; wherein the amount of the absorption enhancing compounds are each present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of alkali metal salicylate, alkali metal lauryl sulphate, edetate and absorption enhancing compounds is less than 50 wt./wt.% of the formulation.

In one embodiment, the process provides an additional step of adding, while continuing vigorous mixing, at least one absorption enhancing compound different from that added in step b), selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid,

linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof.

In one embodiment the alkali metal lauryl sulphate
5 is sodium lauryl sulphate.

In another embodiment the alkali metal salicylate is sodium salicylate.

In a further embodiment the alkali metal edetate may be selected from the group consisting of disodium edetate and dipotassium edetate.

In yet another embodiment, the formulation has a combinations selected from the group consisting of sodium hyaluronate and unsaturated phospholipid, ii) Phospholipon-H and glycolic acid, and iii) sodium
15 hyaluronate and lecithin.

The present invention also provides a process for making a pharmaceutical composition suitable for delivery by means of an aerosol comprising:

a) preparing a pharmaceutical agent composition in micellar form in an aqueous medium which has an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition;

b) slowly adding the micellar proteinic pharmaceutical agent composition to at least one of the absorption enhancing compounds selected from the group consisting

of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, 5 linolenic acid, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, polidocanol alkyl ethers and analogues thereof, triolein and mixtures 10 thereof, while mixing vigorously, to form a mixed micellar composition; and optionally

c) an additional step of adding, while continuing vigorous mixing, at least one micelle forming compound different from that added in step b), selected from the 15 group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, borage oil, evening of primrose oil, 20 glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, and mixtures thereof;

d) mixing the mixed micellar composition resulting 25 from steps a) to c) with a phenol selected from the group consisting of phenol, m-cresol and mixtures thereof; and subsequently

e) placing the formulation into an aerosol dispenser and charging the dispenser a propellant;

30 wherein each of the absorption enhancing compounds are present in a concentration of from 1 to 10 wt./wt.%

For example, hormones which may be administered
25 with the present invention include thyroids, androgens,
estrogens, prostaglandins, somatotropins, gonadotropins,
erythropoetin, interferons, interleukins, steroids and
cytokins. Vaccines which may be administered with the
present invention include bacterial and viral vaccines
30 such as vaccines for hepatitis, influenza, tuberculosis,
canary pox, chicken pox, measles, mumps, rubella,

5

10

25

30

When making the aerosol formulation, the phenol and/or m-cresol and/or isotonic agent are then added.

The preferred propellants are hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. Even more preferred is hydrofluoroalkane (HFA) 134a (1,1,1,2 tetrafluoroethane).

As indicated hereinbefore, the compositions of the present invention require that the pharmaceutical formulation be in mixed micellar form.

In the case of insulin, which is intended for administration through nasal or oral cavities, the first micellar solution may be made by adding a buffer solution to powdered insulin, and then stirring until the powder is dissolved and a clear solution is obtained. A typical buffer solution is an aqueous solution of sodium salicylate and sodium lauryl sulphate and disodium edetate. Typical concentration of sodium salicylate and sodium lauryl sulphate in the aqueous solution are about 3 to 20 wt./wt.% of each compound in the solution. Typically, insulin is present in the micellar solution in an amount which will give a concentration of about 2 to 4 wt./wt.% of the final

formulation. Typically the concentration may be about 10 wt./wt.% of the first micellar composition.

The micellar solution is then added slowly to the first absorption enhancing compound, e.g. lecithin while mixing vigorously, e.g. sonicating, to form a mixed micelle liposomal solution. At least one other absorption enhancing compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein is then added. The mixing may be done with a high speed mixer or sonicator to ensure uniform micelle particle size distribution within the formulation.

Each of the absorption enhancing compounds, when present, is in a concentration of from 1 to 10 wt./wt.% of the total formulation.

Preferred salts of hyaluronic acid are alkali metal hyaluronates, alkaline earth hyaluronates and aluminium hyaluronate. The preferred salt is sodium hyaluronate. The preferred concentration of hyaluronic acid or pharmaceutically acceptable salts of hyaluronic acid is from 1 to 5 wt./wt.% of the total formulation. An even more preferred range is from 1.5 to 3.5 wt./wt.% of the total formulation.

Other ingredients may be added to the mixed
30 micellar solution. For example, flavouring agents,
antioxidants, salts, protease inhibitors or other

In general the size of the micelle particles in the solution is about 1 to 10 nm, and preferably from 1 to 5 nm. Such a size distribution ensures effective absorption of the formulation, and therefore the pharmaceutical agent, through the membranes, for example the membranes in the oral and nasal cavities.

As will be understood, the amount of each component of the formulation will vary depending on the pharmaceutical agent and the site of application. Preferred formulations oral or nasal application have the following combinations: i) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H and sodium hyaluronate; ii) sodium lauryl sulphate, sodium salicylate, disodium edetate, lecithin and sodium hyaluronate; iii) sodium lauryl sulphate, sodium salicylate, disodium edetate, sodium hyaluronate and evening of primrose oil; iv) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H and bacitracin; v) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H, sodium hyaluronate and bacitracin; and vi) sodium lauryl sulphate, sodium salicylate, disodium edetate, sodium hyaluronate, oleic acid and gamma linoleic acid.

For aerosol formulations, the addition of a mixture of phenol and m-cresol is preferred. Such an aerosol formulation may then be charged to an aerosol dispenser and then charged with a propellant, preferably a non-CFC
5 propellant.

The therapeutic compositions of the present invention may be stored at room temperature or at cold temperature. Storage of proteinic drugs is preferable at a cold temperature to prevent degradation of the
10 drugs and to extend their shelf life.

As indicated hereinbefore, generally, oral and nasal are the favourite sites of the administration but the composition can be applied to the rectal and vaginal mucosa. According to the physiologically active peptide
15 or protein used, the dosage form and the site of administration a specific administration method can be selected.

The composition of this invention is generally prepared as microfine mixed micellar particles (1 to 10
20 nm or less) by the virtue of its preparation methods used and suitable combinations of absorption enhancer characteristics.

For oral and nasal application, sprays are preferable, but also drops, chewable tablets, chewable
25 gum and other suitable forms may be used. Utilization of atomizer or aerosol spray devices (metered dose inhalers or nebulizers) can be used to further reduce the particle size for effective inhalation from the nasal or oral cavity so the drug may successfully reach
30 to the specific site and be absorbed. It is also possible to utilize a drug delivery system such that an

00000" 62856560

5 The invention is illustrated by reference to the following examples.

A first experiment was conducted to provide data for comparative purposes. This example does not fall within the scope of the present invention.

In one set of tests, five healthy non-diabetic human volunteers were tested with insulin, by injection. In another set of tests the volunteers were tested with 20 insulin, taken orally. The volunteers fasted from midnight prior to the test, with no food being taken during the 4 hour study.

The average results for the five volunteers, of the

first day's trial (sub-cutaneous injection with 10 units) were as follows:

Table I

	Time*:	0	15	30	60	75	90	120	150	180
5	Avg:	5.8	5.8	5.4	5.0	4.6	4.3	3.8	3.6	3.4
	Time*:	210	240							
	Avg:	4.2	4.5							
	* time in minutes									

The results for each of the five volunteers, of the 10 second day's trial (oral drops with 100 units) were as follows:

Table II

	Time*:	0	15	30	60	75	90	120	150	180
	Subject Nos:									
15	1	6.2	5.8	5.2	5.0	4.9	5.0	5.0	4.8	4.7
	2	5.8	5.4	5.0	4.7	4.9	4.3	5.0	5.5	5.2
	3	4.8	4.6	4.3	4.3	4.4	4.6	4.8	4.7	5.2
	4	6.6	6.1	5.8	5.5	5.1	4.9	5.0	5.0	5.9
	5	6.0	5.8	5.7	5.5	5.1	4.8	4.7	4.9	5.0
20	Time*:		210	240						
	Subject Nos:									
	1		5.5	6.0						
	2		5.8	6.1						
	3		5.5	5.1						
25	4		6.2	6.8						
	5		5.9	6.7						
	* time in minutes									

These tests indicate that compared to the injection method, oral insulin gives a faster onset of action and lowers blood glucose levels without creating hypoglycaemic condition. Due to the hepatic glucose

00000-0288550

production, there was a rebound effect. This is believed to be due to the incomplete absorption of insulin.

Example 2

5 Another experiment, not within the scope of the present invention, was performed for comparative purposes.

Oral insulin (100 units) was formulated in (Phospholipon-H, 10 mg) without any sodium lauryl sulphate, sodium salicylate, edetate or absorption enhancers, to evaluate its efficacy of blood glucose lowering in a fasted state, for healthy volunteers.

Volunteers were asked to fast overnight and not have any breakfast prior to dosing. Volunteers were asked to take this oral insulin formulation in their mouth and swallow it. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours, and the average results for 5 volunteers are shown in Table III.

20 Table III

Time*:0	15	30	45	60	75	90	120	150	180
Avg: 5.6	5.8	5.8	5.7	5.7	5.8	5.7	5.7	5.8	5.7

* time in minutes

This indicates that orally administered insulin
25 with lecithin alone has no effect on blood glucose
lowering.

Example 3

A further experiment, not within the scope of the present invention, was performed for comparative purposes.

Oral insulin (100 units) was formulated with sodium

salicylate and alkali metal edetate (both 5% by wt.) to evaluate its efficacy of blood glucose lowering in fasted state in healthy volunteers.

Volunteers were asked to fast overnight and not have any breakfast prior to dosing. Volunteers were asked to take this oral insulin formulation in their mouth and swallow it. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for 5 volunteers are shown in Table IV.

Table IV

Time*:	0	15	30	45	60	75	90	120	150	180
Avg:	5.8	5.8	5.8	5.9	5.8	5.9	5.7	5.9	6.2	6.0
* time in minutes										

This indicates that orally administered insulin with sodium salicylate and alkali metal edetate alone has no effect on blood glucose lowering. In addition, this formulation caused irritation and burning sensation, which lasted for several hours.

Example 4

A further experiment, not within the scope of the present invention, was performed for comparative purposes.

Oral insulin (100 units) was formulated using sodium salicylate and alkali metal edetate (both 5% by wt.) with Phospholipon-H (10 mg) and tested on healthy subjects. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the results are shown in Table V.

Table V

Time*:	0	15	30	45	60	90	120	180
--------	---	----	----	----	----	----	-----	-----

Avg: 5.3 5.3 5.3 5.4 5.6 5.7 5.7 5.8

* time in minutes

This indicates that orally administered insulin with sodium salicylate, alkali metal edetate and 5 Phospholipon-H has no effect on blood glucose lowering.

Example 5

Another experiment, not within the scope of the present invention, was performed for comparative purposes.

10 Oral insulin (50 units) was formulated using only alkali metal lauryl sulphate (5% by wt). Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for four volunteers are shown in Table VI.

15

Table VI

Time*:	0	15	30	60	90	120	180
Avg:	5.8	5.6	5.4	5.3	5.4	5.4	5.6

* time in minutes

This data shows that orally administered insulin 20 with only alkali metal lauryl sulphate has little metabolic effect on the blood glucose lowering in healthy subjects. This formulation caused substantial burning sensation and irritation in the subjects and lasted for two days.

25 Example 6

Yet another experiment, within the scope of the present invention, was performed.

Mixed micellar oral insulin (50 units) was formulated using alkali metal lauryl sulphate and sodium 30 salicylate (both 4.4% by wt.) and alkali metal edetate (2.2% by wt) with Phospholipon-H (10 mg) and tested on

00000"52888550

healthy volunteers.

The method involved mixing the sodium lauryl sulphate, sodium salicylate and alkali metal edetate with water in a beaker with a magnetic stirrer at medium speed until the ingredients were dissolved, to form buffer solution. Insulin powder was placed in a beaker and to this powder was added the buffer solution. The solution was continuously stirred using a magnetic stir bar until all of the insulin powder was dissolved and a clear solution obtained. The micellar solution so formed was stored in clean glass bottles and refrigerated.

Mixed micellar liposomal insulin was then prepared in a glass beaker, in which was placed the Phospholipon-H and a small amount of isopropyl alcohol. The mixture was stirred at a high speed (1000 rpm) for about 10 minutes to ensure complete dissolution of the Phospholipon-H. To this solution was added the micellar insulin solution very slowly, drop wise, using glass dropper, with continuous stirring at a high speed. The solution was stirred continuously for another 30 minutes at a high speed to ensure uniform micellar particle size distribution.

Samples of the mixed micellar solution were taken orally by the volunteers.

Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for 5 volunteers are shown in Table VII.

Table VII

Time*:	0	15	30	45	60	90	120	150	180
--------	---	----	----	----	----	----	-----	-----	-----

Avg: 6.5 6.1 5.5 5.3 5.3 5.4 5.5 5.5 5.5

* time in minutes

This data shows that orally administered insulin with alkali metal lauryl sulphate combined with the sodium salicylate and alkali metal edetate with Phospholipon-H has a small metabolic effect on blood glucose levels in healthy volunteers.

Example 7

An experiment, within the scope of the present invention, was performed. In this example, the formulation was for oral administration.

Oral insulin (50 units) was formulated using alkali metal lauryl sulphate and sodium salicylate (both 4.4% by wt.) and alkali metal edetate (2.2% by wt.) with Phospholipon-H (10 mg) and sodium hyaluronate (1.1% by wt). This formulation was tested on healthy subjects under fasting condition.

The method involved mixing the sodium lauryl sulphate, sodium salicylate and alkali metal edetate with water in a beaker with a magnetic stirrer at medium speed until the ingredients were dissolved, to form buffer solution. Insulin powder was placed in a beaker and to this powder was added the buffer solution. The solution was continuously stirred using a magnetic stir bar until all of the insulin powder was dissolved and a clear solution obtained. The micellar solution so formed was stored in clean glass bottles and refrigerated.

Mixed micellar liposomal insulin was then prepared in a glass beaker, in which was placed the Phospholipon-H and a small amount of isopropyl alcohol. The mixture

was stirred at a high speed (1000 rpm) for about 10 minutes to ensure complete dissolution of the Phospholipon-H. To this solution was added the micellar insulin solution very slowly, drop wise, using glass 5 dropper, with continuous stirring at a high speed. The solution was stirred continuously for another 30 minutes at a high speed to ensure uniform micellar particle size distribution. The hyaluronate and small amounts of menthol and sorbitol were then added, with continuous 10 stirring.

Samples of the mixed micellar solution were taken orally by the volunteers.

Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and 15 the average results for 5 volunteers are shown in Table VIII.

Table VIII

Time*:	0	15	30	45	60	90	120	150	180
Avg:	6.5	5.9	5.6	5.4	4.9	5.0	4.9	5.2	5.4

20 * time in minutes

This data shows that orally administered insulin with alkali metal lauryl sulphate, sodium salicylate, alkali metal edetate, Phospholipon-H and sodium hyaluronate has resulted in lowering of blood glucose 25 levels in healthy subjects better than the above mentioned formulations.

Example 8

A further experiment, within the scope of the present invention, was performed. In this example, the 30 formulation was for oral administration.

A buffer solution was prepared using 0.5 g sodium

00000 5288860

lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to insulin and mixed, to form micellar insulin.

5 Separately, 100 mg of powdered Phosphatidylcholin-H was added to a glass beaker and to this powder was added 10 mL 50% ethanol. The powder was dissolved completely. To this solution 16 mg (400 units) of micellar insulin solution dissolved in 3 mL of the buffer solution to
10 (give 30 units/mL insulin solution) was added slowly with vigorous mixing, to form a mixed micellar solution. To this was added 0.6 mL of sodium hyaluronate and 0.2 ml of 2% menthol solution containing 3% sorbitol.

In one set of tests, ten Type II diabetic human
15 volunteers who took insulin, by injection three times a day, were studied. In another set of tests the volunteers were tested with insulin, taken orally. The volunteers fasted from midnight prior to the test, with no food being taken during the 4 hour study.

20 On the first day, the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers received 30 units (1 mL volume per drop, approximately 20 drops) of the above-prepared oral
25 insulin (3 times the injection dose). In both tests, blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite.

The results, showing the average for the ten volunteers, were as shown on the following page:

00000"00000000

Table IX

Blood glucose levels (mmol/L)		
Time (minutes)	Oral Dose	Injection
5	(30 units)	(10 units)
0	6.4	6.8
15	5.8	6.9
30	5.4	6.1
45	5.3	5.8
10 60	5.3	5.8
75	5.2	5.8
90	5.2	5.4
105	5.2	5.4
120	5.1	5.2
15 135	5.1	5.1
150	5.2	4.9
165	5.3	4.9
180	5.3	4.8
195	5.4	4.8
20 210	5.4	5.2
225	5.6	5.2
240	5.6	5.4

The results show that the oral insulin formulation of the present invention, at a dosage of three times higher than the injected level, is comparable to the injected insulin.

Example 9

This example illustrates a method for making a mixed micellar formulation according to the present invention.

In a 250 mL capacity glass beaker was added 5 g

5 using the magnetic stir bar, at a medium speed until all the powder was dissolved. The buffer solution was stored in a clean glass bottle at room temperature (pH 6.5).

A 2% menthol solution was then prepared from 100 mg menthol crystals, dissolved in 5 mL ethanol. To this solution was added 5 mg FD & C blue dye. The solution was stirred for 10 minutes and stored in a glass bottle at room temperature.

Mixed micellar liposomal insulin was then prepared in a 50 mL glass beaker, in which was placed 100 mg of phosphatidylcholine (Sigma, type I=EH, hydrogenated). To this powder was added 10 mL of isopropyl alcohol. The mixture was stirred at a high speed (1000 rpm) for about 10 minutes to ensure complete dissolution of the phosphatidylcholine. To this solution was added the micellar insulin solution very slowly, drop wise, using glass dropper, with continuous stirring at a high speed. The solution was stirred continuously for another 30

minutes at a high speed to ensure uniform micellar particle size distribution. To this solution was added 1 mL of the 2% menthol solution and 50 mg sodium hyaluronate. The semi-clear, translucent, light blue colour, liposomal insulin mixed micellar solution (final volume 15 mL) was stored in a clean glass bottle and refrigerated. The solution had a pH of 6.5.

If the phosphatidylcholine powder does not dissolve completely, then heating up to about 45°C may be required, e.g. using a water bath.

It has been found that if the micellar insulin composition is not added slowly, then the mixed micellar formulation will not be formed and the formulation will be gelatinous and sticky.

Example 10

The formulation of Example 9 was tested in a manner similar to that indicated in Example 8 except that the formulation of the present invention was administered nasally.

On the first day, the ten volunteers each received 10 units insulin injection (regular fast acting, Eli Lilly). On the second day, the volunteers received 20 units of the "oral" insulin of Example 9 (2 times the injection dose). The "oral" insulin was administered as drops (0.4 mL volume per drop, approximately 4 large drops in total, i.e. two drops in each nostril).

The results, showing the average for the ten volunteers, were as follows:

Table X

Time (minutes)	Blood glucose levels (mmol/L)	
	Nasal Dose	Injection

	(20 units)	(10 units)
0	7.4	6.8
15	6.7	7.0
30	5.9	6.8
5 45	5.3	6.3
60	5.0	6.3
75	5.2	5.8
90	5.1	5.2
105	5.0	5.0

10

Table X (continued)

Blood glucose levels (mmol/L)		
Time (minutes)	Nasal Dose (20 units)	Injection (10 units)
120	4.6	5.2
15 135	4.5	4.2
150	4.3	4.6
165	4.3	4.0
180	4.8	4.1
195	5.3	4.3
20 210	5.4	4.5
225	5.7	4.7
240	5.6	5.0

The results show that the nasal insulin formulation of the present invention, at a dosage of twice the injected level, is comparable to the injected insulin.

Example 11

The formula of Example 9 was taken and tests performed to determine the insulin action on meal glucose on healthy volunteers.

Usually, diabetic patients take an insulin injection 30 minutes prior to a meal, because injected

insulin takes a long time to take effect. Injected insulin is slowly absorbed into bloodstream within 60 minutes and has metabolic effect on meal glucose levels.

The mixed micellar formulation of Example 9 was tested in healthy volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin.

In one set of tests, ten healthy non-diabetic human volunteers were tested with insulin, by injection. In another set of tests the volunteers were tested with insulin, taken orally. The volunteers fasted from midnight prior to the tests, with food being taken 30 minutes after dosing. The meals were standard Sastacal 240 mL liquid diet approved by the Diabetic Society, containing 400 calories.

On the first day, the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers received 30 units of the above-prepared oral insulin (3 times the injection dose). In both tests, blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite. The results are shown on the following page:

Table XI

Blood glucose levels (mmol/L)			
Time (minutes)		Oral Dose	Injection
		(30 units)	(10 units)
5	0	5.7	5.5
	15	5.2	5.6
	30	5.0	5.4
	45	5.3	5.4
10	60	5.4	5.6
	75	6.3	6.6
	90	6.9	7.0
	105	6.0	5.9
	120	5.8	5.6
15	135	5.5	5.1
	150	5.1	4.8
	165	4.9	4.6
	180	4.8	4.3

The results indicate that the oral insulin helps control meal glucose levels in healthy volunteers when compared to injected insulin.

Example 12

The mixed micellar formulation of Example 9 was tested in diabetic volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin.

In one set of tests, ten Type II diabetic human volunteers who took insulin, by injection three times a day, were studied. In another set of tests the volunteers were tested with insulin, taken orally. The volunteers fasted from midnight prior to the tests, with

food being taken 30 minutes after dosing. The meals were standard Sastacal 240 mL liquid diet approved by the Diabetic Society, containing 400 calories.

On the first day, the volunteers received 10 units 5 insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers received 30 units of the above-prepared oral insulin (3 times the injection dose). In both tests, blood glucose levels were monitored every 15 minutes by 10 Bayer's Glucometer Elite.

The average results for the 10 volunteers were as follows:

Table XII

		Blood glucose levels (mmol/L)	
15	Time (minutes)	Oral Dose	Injection
		(30 units)	(10 units)
	0	8.8	8.7
	15	8.1	8.8
	30	8.0	8.9
20	45	8.4	10.1
	60	10.2	11.8
	75	11.8	11.8
	90	12.3	12.2
	105	10.8	11.2
25	120	9.6	10.4
	135	8.1	8.4
	150	6.9	7.3
	165	6.2	6.5
	180	4.8	4.3

30 The results indicate that oral insulin helps to control meal glucose levels in diabetic patients when

compared to injected insulin.

Example 13

A chewable gum insulin formulation was prepared by vigorously stirring the liposomal insulin mixed micellar solution of Example 9 while adding guar gum, beeswax, powdered acacia, oleic acid, gamma-linoleic acid and sorbitol. For each 30 units of insulin, the mixture contained 100 mg guar gum, 50 mg beeswax, 50 mg powdered acacia, 100 mg oleic acid, 100 mg gamma-linoleic acid and 1 mL 3% sorbitol in ethanol solution. The mixture was then poured into a flat tray coated with polytetrafluoroethylene until the mixture was about 10 mm deep. The mixture then solidified and after solidification was cut into sticks about 1 cm by 3 cm. Each stick contained about 30 units insulin.

The mixed micellar formulation in chewable stick form was tested in diabetic volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin.

In one set of tests, five Type II diabetic human volunteers who took insulin, by injection three times a day, were studied. In another set of tests the volunteers were tested with the chewable gum insulin, taken orally. The volunteers fasted from midnight prior to the tests, with food being taken 30 minutes after dosing. The meals were standard Sastacal 240 mL liquid diet approved by the Diabetic Society, containing 400 calories.

On the first day, the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the

volunteers received 30 units of the above-prepared chewable gum oral insulin (3 times the injection dose). In both tests, blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite.

5 The average results for the five volunteers were as follows:

10

Table XIII

Blood glucose levels (mmol/L)

Time (minutes)		Oral Dose (30 units)	Injection (10 units)
	0	9.1	8.8
15	15	9.3	8.2
	30	9.3	8.0
	45	10.2	8.4
	60	11.2	9.2
	75	12.1	10.3
20	90	12.9	11.8
	105	13.2	11.6
	120	12.8	11.0
	135	12.2	10.2
	150	11.6	9.6
25	165	11.0	9.5
	180	10.6	9.1
	195	10.0	8.7
	210	9.5	8.2
	225	8.8	8.0
30	240	8.2	7.5

Example 14

Another experiment, within the scope of the present invention, was performed. In this example, the formulation was for oral administration.

A buffer solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to 8 mg (200 units) insulin and mixed, to form micellar insulin.

To this micellar solution were added 0.2 g bacitracin and 0.5 g evening of primrose oil and the solution was mixed vigorously to form a mixed micellar insulin solution (about 20 units/mL).

Six human volunteers were studied. The volunteers fasted from midnight prior to the test, with no food being taken during the 4 hour study.

On the first day, the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly). On the second day, the volunteers received 20 units of the above-prepared oral insulin (twice the injection dose). In both tests, blood glucose levels were monitored at intervals by Bayer's Glucometer Elite.

The results, showing the average for the six volunteers, were as follows:

		<u>Table XIV</u>	
		Blood glucose levels (mmol/L)	
Time (minutes)		Oral Dose	Injection
		(20 units)	(10 units)
0		8.8	7.9
30	15	8.4	7.9
	30	8.1	8.2

	45	7.4	8.3
	60	6.3	7.6
	90	5.1	6.2
	120	5.0	5.2
5	150	4.8	4.6
	180	5.1	3.9
	210	5.3	4.4
	240	5.6	5.2

The results show that the oral insulin formulation
10 of the present invention, at a dosage of twice the
injected level, is comparable to the injected insulin.

Example 15

A further experiment was performed to show another
method of making the mixed micellar formulation of the
15 present invention.

In a 250 mL round bottom flask was added 100 mg of
saturated lecithin powder (Phospholipón-90H) purchased
from the American Lecithin Co. To this powder was added
5 mL of absolute ethanol (USP grade). The flask was
20 then attached to a rotary evaporator equipped with the
vacuum pump and nitrogen inlet for inert atmosphere
condition to minimize oxidation of the lecithin. The
flask was rotated at 100-150 rpm under vacuum. The
solution in the flask was heated to 60°C by means of
25 water bath to dissolve the powder completely. After
complete dissolution of the powder, heating was stopped
and the rotation speed was increased to 300 rpm, under
vacuum in nitrogen atmosphere until the alcohol
evaporated completely, leaving a uniform film on the
30 side of the flask. The rotation was continued for at
least 30 minutes to ensure uniform coating of film on

the wall and complete solvent removal. After 30 minutes the rotation was stopped and the vacuum was released.

To this flask was added micellar insulin solution which had been prepared from an aqueous solution of insulin, sodium lauryl sulphate, sodium salicylate and disodium edetate. The flask was shaken with the help of shaker plate. Shaking was continued for at least 30 minutes and then the solution was sonicated with a high frequency sonicating probe for another 60 minutes in order to form small uniform mixed micelles. The mixed micelles so obtained were analyzed by Malvern Zeta (trade mark) particle size distribution measurement equipment equipped with the laser light scattering device. The mixed micelles particle size distribution obtained by this method was between 2 and 9nm. To this solution was added 1 mL of 2% menthol solution and 50 mg sodium hyaluronate. The semi-clear, translucent, light blue colour solution (final volume 10 mL) was stored in a clean glass bottle and refrigerated. The solution had a pH of 6.5.

Example 16

Another experiment, within the scope of the present invention, was performed.

A buffer solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to 8 mg (200 units) insulin and mixed, to form micellar insulin.

To this micellar solution were added 0.5 g borage oil and the solution was mixed vigorously to form a

1. A process for making a pharmaceutical composition suitable for delivery through mucosal membranes comprising:

- 5 a) preparing a pharmaceutical agent composition in micellar form in an aqueous medium which has an alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, an alkali metal C8 to C22 alkyl sulphate in
10 a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition and a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition;
- 15 b) slowly adding the micellar proteinic pharmaceutical agent composition, while mixing, to at least one absorption enhancing compound, while continuing to mix vigorously, said absorption enhancing compounds being selected from the group consisting of lecithin,
20 hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine
25 and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, polidocanol alkyl ethers and analogues thereof, triolein and mixtures thereof, wherein the amount of each absorption enhancing compound is present in a concentration of from 1 to
30 10 wt./wt.% of the total formulation, and the total concentration of alkali metal salicylate, alkali metal

C8 to C22 alkyl sulphate, edetate and absorption enhancing compounds is less than 50 wt./wt.% of the formulation.

2. A process according to Claim 1 wherein there is an additional step of adding, while continuing mixing, at least one absorption enhancing compound different to that added in step b), selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof.

15 3. A process according to Claim 1 wherein the
absorption enhancing compound in step b) is selected
from the group consisting of saturated phospholipid,
unsaturated phospholipid, phosphatidylcholine,
phosphatidyl serine, sphingomyelin,
20 phosphatidylethanolamine, cephalin, lecithin,
lysolecithin and mixtures thereof.

4. A process according to Claim 1 wherein one of the absorption enhancing compounds is lecithin and another absorption enhancing compound is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid and mixtures thereof, the concentration such absorption enhancing compound being from about 1 to about 5 wt./wt.%.

5. A process according to Claim 1 wherein the micellar
30 absorption enhancing compounds comprise combinations
selected from the group consisting of i) saturated

5 6. A process according to Claim 1 wherein the
proteinic pharmaceutical agent is selected from the
group consisting of insulin, heparin, so-called low
molecular weight heparin, hirulog, hirugen, huridin,
interferons, interleukins, cytokines, mono and
10 polyclonal antibodies, chemotherapeutic agents,
vaccines, glycoproteins, bacterial toxoids, hormones,
calcitonins, insulin like growth factors (IGF), glucagon
like peptides (GLP-1), large molecule antibiotics,
protein based thrombolytic compounds, platelet
15 inhibitors, DNA, RNA, gene therapeutics, antisense
oligonucleotides, opioids, narcotics, analgesics,
NSAIDS, steroids, hypnotics, pain killers and morphine.

c) while continuing to mix, adding at least one absorption enhancing compound selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof;

wherein the amount of lecithin and the absorption

enhancing compound are each present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of alkali metal salicylate, alkali metal C8 to C22 alkyl sulphate, edetate and
5 absorption enhancing compounds is less than 50 wt./wt.% of the formulation.

8. A process according to Claim 1 wherein the absorption enhancing compound is formed into a film prior to the addition of the micellar pharmaceutical
10 agent composition.

9. A process according Claim 1 wherein subsequent to the addition of the micellar pharmaceutical agent composition a second absorption enhancing compound is added, said second absorption enhancing compound being
15 different from the absorption enhancing compound previously used.

10. A process according to Claim 1 a phenol selected from the group consisting of phenol, methyl phenol and mixtures thereof are added to the micellar formulation
20 and the resulting formulation placed in a container, and the container is subsequently charged with a propellant.

11. A process according to Claim 10 wherein the propellant is selected from the group consisting of tetrafluoroethane, tetrafluoropropane,
25 dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.

12. A process according to Claim 1 wherein the pharmaceutical agent is insulin.

13. A process according to Claim 11 wherein the
30 pharmaceutical agent is insulin.

14. A mixed micellar pharmaceutical formulation

00000" 52888860

comprising a pharmaceutical agent in micellar form,
water, an alkali metal C8 to C22 alkyl sulphate in a
concentration of from 1 to 10 wt./wt.% of the total
formulation, a pharmaceutically acceptable edetate in a
5 concentration of from 1 to 10 wt./wt.% of the total
formulation, at least one alkali metal salicylate in a
concentration of from 1 to 10 wt./wt.% of the total
formulation, and at least one absorption forming
compound, said absorption forming compounds being
10 selected from the group consisting of lecithin,
hyaluronic acid, pharmaceutically acceptable salts of
hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic
acid, lactic acid, chamomile extract, cucumber extract,
oleic acid, linolenic acid, borage oil, evening of
15 primrose oil, menthol, trihydroxy oxo cholanylglycine
and pharmaceutically acceptable salts thereof, glycerin,
polyglycerin, lysine, polylysine, polidocanol alkyl
ethers and analogues thereof, triolein and mixtures
thereof, wherein the amount of each absorption enhancing
20 compound is present in a concentration of from 1 to
10 wt./wt.% of the total formulation, and the total
concentration of absorption enhancing compounds are less
than 50 wt./wt.% of the formulation.

15. A mixed micellar pharmaceutical formulation
25 according to Claim 14, in which one of the absorption
enhancing compounds is lecithin.

16. A formulation according to Claim 14 wherein the
alkali metal C8 to C22 alkyl sulphate is sodium lauryl
sulphate and the alkali metal salicylate is sodium
30 salicylate.

17. A formulation according to Claim 15 wherein the

00000" 5288E560

18. A formulation according to Claim 15 wherein the other absorption enhancing compound is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid and mixtures thereof, the concentration such absorption enhancing compound being from about 1 to about 5 wt./wt. %.

20. A formulation according to Claim 14 wherein the
30 pharmaceutical agent is selected from the group
consisting of insulin, heparin, so-called low molecular

A mixed micellar pharmaceutical formulation includes a micellar proteinic pharmaceutical agent, an alkali metal C8 to C22 alkyl sulphate, alkali metal salicylate, a pharmaceutically acceptable edetate and at least one absorption enhancing compounds. The absorption enhancing compounds are selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein and mixtures thereof. The amount of each absorption enhancing compound is present in a concentration of from 1 to 10 wt./wt.% of the total formulation, and the total concentration of absorption enhancing compounds are less than 50 wt./wt.% of the formulation.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 8/30/00. OMB 0851-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input checked="" type="checkbox"/> Declaration Submitted with Initial Filing OR <input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	358594-00010-2
	First Named Inventor	Pankaj Modi
	COMPLETE IF KNOWN	
	Application Number	/
	Filing Date	
	Group Art Unit	
	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Method for Administering Insulin to the Buccal Region

the specification of which (Title of the invention)

☒ is attached hereto
OR
☐ was filed on (MM/DD/YYYY) as United States Application Number or PCT International Application Number and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
09/216,733	12/21/1998	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☒ Customer Number 3705 →

Place Customer
Number Bar Code
Label here

☐ OR Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number OR ☒ Correspondence address below

Name	Diane R. Meyers				
Address	Eckert Seamans Cherin & Mellott, LLC				
Address	600 Grant Street, 44th Floor				
City	Pittsburgh	State	PA	ZIP	15219
Country	US	Telephone	412/566-2036	Fax	412/566-6099

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])	Family Name or Surname
Pankaj	Modi

Inventor's Signature	<i>Pankaj Modi</i>			Date	28/3/00
Residence: City	Ancaster	State	Ontario	Country	Canada
Post Office Address	519 Golflinks Road				
Post Office Address					
City	Ancaster	State	Ontario	ZIP	L9G4X6
				Country	

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto